The impact of targeted therapy on management of metastatic renal cell carcinoma: Trends in systemic therapy and cytoreductive nephrectomy utilization

Urology

Volumn 85, Issue 2, 2015, Pages 442-451

  Psutka, Sarah P ^a   Kim, Simon P ^b,c   Gross, Cary P ^c,d   Van Houten, Holly ^a   Thompson, R Houston ^a   Abouassaly, Robert ^b   Weight, Christopher ^e   Boorjian, Stephen A ^a   Leibovich, Bradley C ^a   Shah, Nilay D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c YALE UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; ELIXHAUSER COMORBIDITY INDEX; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; SYSTEMIC THERAPY; CARCINOMA, RENAL CELL; CYTOREDUCTIVE SURGERY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SECONDARY; TRENDS; UTILIZATION;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY;

EID: 84921475147     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.10.040     Document Type: Article

References (29)

1. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463
2. P. Russo, M. Synder, and A. Vickers Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer ScientificWorldJournal 7 2007 768 778
3. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
4. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
5. R.J. Motzer, B. Escudier, and P. Tomczak Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 2013 552 562
6. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
7. B. Escudier, and M. Gore Axitinib for the management of metastatic renal cell carcinoma Drugs R D 11 2011 113 126
8. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
9. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
10. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
11. B. Ljungberg, N.C. Cowan, and D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
12. B. Ljungberg The role of metastasectomy in renal cell carcinoma in the era of targeted therapy Curr Urol Rep 14 2013 19 25
13. R.C. Flanigan, G. Mickisch, and R. Sylvester Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071 1076
14. G.H. Mickisch, A. Garin, and H. van Poppel Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
15. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
16. D.C. Miller, C.S. Saigal, and J.L. Warren External validation of a claims-based algorithm for classifying kidney-cancer surgeries BMC Health Serv Res 9 2009 92 6963-9-92
17. A. Elixhauser, C. Steiner, and D.R. Harris Comorbidity measures for use with administrative data Med Care 36 1998 8 27
18. D. Cella, J.Z. Li, and J.C. Cappelleri Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial J Clin Oncol 26 2008 3763 3769
19. D. Cella, M.D. Michaelson, and A.G. Bushmakin Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis Br J Cancer 102 2010 658 664
20. C.K. Tsao, A.C. Small, and M. Kates Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis World J Urol 31 2013 1535 1539
21. S.L. Conti, I.C. Thomas, and J.C. Hagedorn Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era Int J Cancer 134 2014 2245 2252
22. S.K. Pal, R.A. Nelson, and N. Vogelzang Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era PLoS One 8 2013 e63341
23. B.F. Chapin, S.E. Delacroix Jr., and S.H. Culp Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma Eur Urol 60 2011 964 971
24. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
25. D.Y. Heng, J.C. Wells, and B.I. Rini Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium Eur Urol 66 2014 704 710
26. A. Bamias, K. Tzannis, and A. Papatsoris Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study Clin Genitourin Cancer 12 2014 373 383
27. L. Tosco, H. Van Poppel, and B. Frea Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma Eur Urol 63 2013 646 652
28. S.H. Culp, N.M. Tannir, and E.J. Abel Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116 2010 3378 3388
29. J.R. Lieffers, V.E. Baracos, and M. Winget A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data Cancer 117 2011 1957 1965